Short answer
TREACE MEDICAL CONCEPTS, INC. (TMCI) filed an 8-K current report with the SEC on August 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.
TREACE MEDICAL CONCEPTS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release issued August 7, 2026 and furnished as Exhibit 99.1
- Investor focus: financial performance details and outlook in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $45.4M, down 4% YoY, while operating expenses fell 8% to $50.6M
- Net loss improved to $15.9M from $17.4M; adjusted EBITDA loss narrowed to $3.5M from $3.6M
- Cash, equivalents, and marketable securities totaled $45.6M, with an additional $115M credit facility subject to conditions
- Full-year revenue guidance raised to $204M-$212M; adjusted EBITDA loss outlook improved to $3M-$5M
- Portfolio adoption increased to approximately 40% of Lapiplasty surgeon users from 35% in Q1 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TREACE MEDICAL CONCEPTS, INC. 8-K filings
Get the next TMCI 8-K as it lands
Follow TMCI for push alerts, or ask the research agent what this filing means.